Brian Druker

Anatomy of a Breakthrough in Targeted Cancer Treatments

Brian Druker

Talk: Anatomy of a Breakthrough in Targeted Cancer Treatments

Brian Druker, winner of the Lasker Prize and Director of the Knight Cancer Institute, is one of the developers of Gleevec, a triumph of rational, science-driven drug design and targeted cancer therapy. Originally developed to treat chronic myeloid leukemia, Gleevec is now used in more than 10 indications by hundreds of thousands of adults and children each year. The Knight Cancer Institute, which Brian leads, is devoted to development of personalized cancer therapies. Supported by a recent billion dollar fundraising effort and state bond measure, its new focus is the early detection of cancer.

Brian Druker

Brian J. Druker is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine.